AB1 in Adult Patients with Sickle Cell Disease (SCD) ((SCD))
A Phase 1/2, Open-Label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB1 in Adult Patients with Sickle Cell Disease (SCD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 4 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 16mg, and 32mg.
- Cohort 1 - Two (2) patients will be enrolled at the 2mg dose level for 8 weeks of treatment. After both patients have received at least 4 weeks of treatment, if there are no adverse events ≥Grade 2 that are related (possibly, probably, or definitely) to the study drug, then the study will proceed to the next dose level. Note that if ≥Grade 2 toxicity is seen at this dose level, the study drug regimen may be modified (eg, twice or thrice weekly versus daily dosing).
- Cohort 2 - Two (2) patients will be enrolled at the 4mg dose level for 8 weeks of treatment. After both patients have received at least 4 weeks of treatment, if there are no adverse events ≥Grade 2 that are related to the study drug, then the study will proceed to the next dose level.
- Cohort 3 - Three (3) patients will be enrolled at the 8mg dose level for 8 weeks of treatment. After all patients have received at least 4 weeks of treatment, if <2 patients experience a related adverse event ≥Grade 2, then the study will proceed to the next dose level. (If ≥2 patients experience a related adverse event ≥Grade 2, the previous cohort will be expanded.)
- Cohort 4 - Three (3) patients will be enrolled at the 10mg dose level for 8 weeks of treatment. After all patients have received at least 4 weeks of treatment, if <2 patients experience a related adverse event ≥Grade 2, then the study will proceed to the next dose level. (If ≥2 patients experience a related adverse event ≥Grade 2, the previous cohort will be expanded.)
- Cohort 5 - Three (3) patients will be enrolled at the 12mg dose level for 8 weeks of treatment. After all patients have received at least 4 weeks of treatment, if <2 patients experience a related adverse event ≥Grade 2, then the study will proceed to the next dose level. (If ≥2 patients experience a related adverse event ≥Grade 2, the previous cohort will be expanded.)
- Cohort 6 - Three (3) patients will be enrolled at the 16mg dose level for 8 weeks of treatment. After all patients have received at least 4 weeks of treatment, if <2 patients experience a related adverse event ≥Grade 2, then the study will proceed to the next and final dose level. (If ≥2 patients experience a related adverse event ≥Grade 2, the previous cohort will be expanded.)
- Cohort 7 - Three (3) patients will be enrolled at the 32mg dose level for 8 weeks of treatment.
- An additional cohort may be explored at the 24mg dose level if deemed appropriate based on safety and activity parameters.
If there are any adverse events Grade ≥2 that are related (possibly, probably, or definitely) to study drug, at the 4mg cohort or in ≥2 patients in any subsequent cohort, the dose may be reduced to the previous cohort and an additional 3-6 patients (total of up to 9) may be enrolled into that cohort. Additionally, if Hbf levels increase >15% (expressed as a percentage of total Hb) in any cohort, the cohort can be expanded to an additional 3 to 6 patients as well as continue to the next cohort if safety parameters have been met. In the expansion cohort, patients will receive study drug treatment for an additional 4 weeks (total of 12 weeks)..
Approximately 6 to 39 patients may be enrolled for the entire study. Patients are eligible to enroll in a higher cohort of the study after a minimum of one-month washout from AB1 dosing, if their HbF levels return to baseline (<15%) and the investigator deems the patient eligible.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Nirmish Shah, MD
- Phone Number: 919-668-5128
- Email: nirmish.shah@duke.edu
Study Contact Backup
- Name: Lindsey Ford
- Phone Number: 919-684-6180
- Email: lindsey.ford@duke.edu
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Augusta University Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Greenville, North Carolina, United States, 27834
- East Carolina University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written, informed consent
- Age 18 to 45 years of age, inclusive at screening
- Confirmed SS or S-b0-thalassemia SCD
- Sickle crisis rate of 2-10 within the past year with no crisis in the last 28 days
- HbF <8.6% of total Hb at screening
- Regular compliance with comprehensive care and previous therapy -
Exclusion Criteria:
- Experienced severe sepsis or septic shock within the previous 12 weeks
- Febrile illness in the 1 week prior to baseline visit
- Acute complications due to SCD (i.e., hospitalization, acute pain, or acute chest syndrome) in the 28 days prior to screening visit
- Plans for hospitalization, surgery, or other major procedures during the duration of the study or between screening and baseline
- ALT ≥2X the upper limit of normal or albumin <2.0 mg/dL or direct (conjugated) bilirubin ≥ 1.5 mg/dl*
- Serum creatinine >2.9 mg/dL and calculated creatinine clearance <30 mL/min# *
- Platelet count >800 x 109/L OR <150 x 109/L*
- Absolute neutrophil count <1.5 x 109/L*
- Currently pregnant or breastfeeding
- Female of active childbearing potential$ who is unwilling or unable to adhere to the contraception requirements specified in the protocol
- Male with female partner(s) of childbearing potential$ who is unwilling or unable to adhere to the contraception requirements specified in the protocol
- Altered mental status or recurrent seizures requiring anti-seizure medications
- Moribund or any concurrent disease (e.g., hepatic, renal, cardiac, metabolic) of such severity that death within 24 weeks is likely
- Concurrent diagnosis of malignancy including MDS, leukemia, or an abnormal karyotype
- Known Vitamin-B12, folate, or iron deficiency
- New York Heart Association (NYHA) class III/IV status
- Eastern Co-operative Oncology Group (ECOG) performance status ≥3
- Participant is on chronic transfusion therapy (e.g., for history of TIA or stroke) and medically contraindicated to discontinue transfusions (unless multiple allo-antibodies prevent the patient from getting transfusions as scheduled)
- Blood transfusion in the 28 days prior to screening visit or between screening and baseline visits
- Known history of illicit drug or alcohol abuse within the past 12 months.
- Current treatment with Oxbryta or Adakveo (must be off therapy for 30 days for Oxbryta with no plans to restart and off therapy for 3 months for Adakveo with no plans to restart)
- Other experimental or investigational drug therapy in the past 28 days -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AB1
AB1 is the investigational product in this study taken orally, once daily, for 8 weeks.
This will be an open-label, dose escalating study with a starting dose of 2mg.
Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg.
|
This will be an open-label, dose escalating study with a starting dose of 2mg.
Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg.
Each dose will be taken orally, once daily, for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of adverse events/serious adverse events as measured by patient report/medical records
Time Frame: From the time of consent up to 12 months
|
From the time of consent up to 12 months
|
|
|
Number of ≥Grade 2 study related adverse events as measured by patient report/medical record
Time Frame: From the time of consent up to 12 months
|
Adverse events that cause enough discomfort to interfere with usual daily activity; may warrant therapeutic intervention
|
From the time of consent up to 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Cmax as measured by blood test
Time Frame: Baseline, week4, week8, week10
|
Baseline, week4, week8, week10
|
|
Change in tmax as measured by blood test
Time Frame: Baseline, week4, week8, week10
|
Baseline, week4, week8, week10
|
|
Change in t1/2 as measured by blood test
Time Frame: Baseline, week4, week8, week10
|
Baseline, week4, week8, week10
|
|
Change in AUC o-t as measured by blood test
Time Frame: Baseline, week4, week8, week10
|
Baseline, week4, week8, week10
|
|
Change in dose normalized AUC o-inf as measured by blood test
Time Frame: Baseline, week4, week8, week10
|
Baseline, week4, week8, week10
|
|
Change in CL as measured by blood test
Time Frame: Baseline, week4, week8, week10
|
Baseline, week4, week8, week10
|
|
Change in Vz as measured by blood test
Time Frame: Baseline, week4, week8, week10
|
Baseline, week4, week8, week10
|
|
Change in Vss as measured by blood test
Time Frame: Baseline, week4, week8, week10
|
Baseline, week4, week8, week10
|
|
Change in percentage of total percentage of total hemoglobin (HB) as measured by HPLC
Time Frame: Screening, baseline, week2,week4, week6, week8, week10, week12
|
Screening, baseline, week2,week4, week6, week8, week10, week12
|
|
Change in percentage of F-cells measured by flow cytometry
Time Frame: Screening, baseline, week2,week4, week6, week8, week10, week12
|
Screening, baseline, week2,week4, week6, week8, week10, week12
|
|
Change in percent reticulocytes as measured by blood tests
Time Frame: Screening, baseline, week2,week4, week6, week8, week10, week12
|
Screening, baseline, week2,week4, week6, week8, week10, week12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nirmish Shah, MD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00110179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.